Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Combination therapies in multiple sclerosis.

Ralf Gold1

  • 1University of Bochum, St. Josef-Hospital, Dept. of Neurology, Gudrunstr. 56, 44791, Bochum, Germany. Ralf.Gold@rub.de

Journal of Neurology
|April 9, 2008
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

General principles and escalation options of immunotherapy in autoantibody-associated disorders of the CNS.

Neurological research and practice·2020
Same author

Severe pneumonia with formation of a pulmonary cavity associated with long-term rituximab therapy in multiple sclerosis.

Neurological research and practice·2020
Same author

Comprehensive approaches for diagnosis, monitoring and treatment of chronic inflammatory demyelinating polyneuropathy.

Neurological research and practice·2020
Same author

TDP-43 as structure-based biomarker in amyotrophic lateral sclerosis.

Annals of clinical and translational neurology·2020
Same author

New Approaches to Critical Illness Polyneuromyopathy: High-Resolution Neuromuscular Ultrasound Characteristics and Cytokine Profiling.

Neurocritical care·2020
Same author

High-dose biotin in multiple sclerosis: the end of the road.

The Lancet. Neurology·2020
Same journal

The dual role of mTOR in multiple sclerosis pathophysiology: a systematic review.

Journal of neurology·2026
Same journal

Brain-first versus body-first Parkinson's disease: Differential findings on pupillary, brainstem and vagus sonography.

Journal of neurology·2026
Same journal

Spontaneous intracranial hypotension due to pelvic cerebrospinal fluid leak.

Journal of neurology·2026
Same journal

Morbidity and medication use preceding a diagnosis of late-onset Alzheimer's disease: a Danish nationwide study.

Journal of neurology·2026
Same journal

Comorbid autoimmune disease in stiff-person syndrome spectrum disorder: a systematic review and meta-analysis.

Journal of neurology·2026
Same journal

Tetrahydrocannabinol/cannabidiol in the treatment of restless legs syndrome.

Journal of neurology·2026
See all related articles

Exploring combination therapies for multiple sclerosis (MS) shows promise for improved efficacy. While combining beta-interferon and glatiramer acetate is under investigation, evidence for other beta-interferon combinations remains limited.

Area of Science:

  • Neuroimmunology
  • Clinical Pharmacology

Background:

  • Significant advancements in understanding multiple sclerosis (MS) pathophysiology.
  • Increased availability of immunomodulatory and immunosuppressive therapies for MS, particularly relapsing-remitting MS.
  • Therapeutic efficacy of current MS treatments can be limited in individual patients.

Purpose of the Study:

  • To evaluate the potential benefits of combination therapies in multiple sclerosis.
  • To explore additive or synergistic effects of combining different immunomodulatory agents.
  • To assess the clinical efficacy and safety of combination treatments for MS.

Main Methods:

  • Review of current therapeutic landscape for multiple sclerosis.
  • Analysis of ongoing clinical trials, including a Phase III trial for beta-interferon and glatiramer acetate combination.

Related Experiment Videos

  • Examination of existing data on combinations of beta-interferons with other agents (statins, natalizumab, azathioprine).
  • Assessment of preliminary data for glatiramer acetate combinations (mitoxantrone, minocycline).

    • Main Results:

    • Combination of beta-interferon and glatiramer acetate is currently under Phase III trial evaluation.
    • Previous combination studies with beta-interferons have not shown unequivocal benefits.
    • Preliminary data suggests potential benefits for glatiramer acetate in combination with mitoxantrone and minocycline.

    Conclusions:

    • Combination therapies for multiple sclerosis (MS) are being explored to enhance clinical efficacy and manage side effects.
    • While combining first-line treatments like beta-interferon and glatiramer acetate is under investigation, evidence for other beta-interferon combinations is limited.
    • Further research into specific drug combinations, such as glatiramer acetate with mitoxantrone or minocycline, may offer promising therapeutic strategies for MS management.